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A B S T R A C T  
Objective: To compare the effectiveness of spot urinary microalbumin excretion for detection of early diabetic 
nephropathy in comparison with 24 hours urinary proteins in patients with diabetes mellitus. 
Materials and Methods: The study was conducted at Nephrology Department of Pakistan Institute of medical Sciences, 
Islamabad. It included diagnosed cases of type 1 or 2 diabetes mellitus, (with type 2 diabetes of any duration and type 1 
diabetes of more than 5 years duration) who tested negative for overt albuminuria on standard urinary dipstick done on 
two occasions. Each patient was provided a plastic container with capacity of 4000 ml for 24 hours collection of urine. 
The study group subjects were requested to provide early morning urine sample for spot urine test. Urinary microalbumin 
was determined by the immunoturbidimetric method. 24-hour urinary albumin excretion was determined by photometric 
test according to biuret method. SPSS version 12 was used to record and analyze the gathered data. Descriptive 
statistic and frequencies of the spot urine albumin and 24 hours urinary albumin were measured. The sensitivity, 
specificity, negative predictive value, positive predictive value, accuracy and efficacy of spot urine microalbumin test was 
calculated in comparison to 24-hour urine protein test. 
Results: Out of 289 patients of Diabetes mellitus included in the study, 39 (13.5%) had type 1 Diabetes mellitus and 250 
(86.5%) had type 2 Diabetes mellitus. The mean age of the patients was 54.079.5 years. Among total patients 113 
(39.1%) patients had positive 24-hour urine protein and 98 (33.9%) had positive spot urine microalbumin test. The 
sensitivity, specificity, positive predictive value and negative predictive value of the spot urinary microalbumin test in 
comparison to 24-hour urine protein test was 83%, 97.7%, 96% and 90% respectively. In total spot urinary microalbumin 
test was accurate in 92% cases. When the results of spot urine microalbumin test and 24-hour urinary protein test were 
compared using the chi-square test, it was found that patients with a positive spot urine microalbumin test had a 
statistically significant probability of having a confirmed diabetic nephropathy on 24-hour urinary protein test; p= 0.00. 
Conclusion: Spot urine microalbumin test is a highly sensitive and specific tool in the diagnosis of early diabetic 
nephropathy with high positive predictive value. Spot urine microalbumin test offers the advantage of speed, simplicity 
and early diagnosis. Spot urine microalbumin test has acceptable accuracy as compared to 24-hour urine protein test. 
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I n t r o d u c t i o n  
 
Diabetes Mellitus (DM) is one of the major illness affecting 
284 millions of people worldwide. It caused approximately 
88014 deaths in Pakistani population at the end of year 
2010, according to International Diabetes Federation.1 
Diabetic nephropathy affects 25 percent of patients with 
diabetes that progress to chronic renal failure.2 It occurs 
both in type 1 and type 2 DM. Diabetic kidney disease 
presents in its earliest stage with microalbuminuria 
(defined as albumin–to–creatinine ratio between 30-299 
μg albumin/milligram of creatinine) in the urine, also called 
as incipient nephropathy. With the disease progression, 
urine albumin levels increase until the patient develops 
overt proteinuria (defined as more than 300mg per 24 
hours or more than 200 mcg per minute). Overt 
proteinuria is followed by a gradual decrease in 
glomerular filtration rate that ultimately leads to kidney 
failure.3 
Increased urinary protein excretion is the earliest clinical 
manifestation of diabetic nephropathy.4,5 However, when 
assessing protein excretion, the urine dipstick is a 
relatively insensitive marker for initial increases in protein 
excretion, not becoming positive until protein excretion 
exceeds 300 to 500 mg/. Using a specific assay for 
albumin is a more sensitive technique. The normal rate of 
albumin excretion is less than 20 mg/day (15 µg/min); 
persistent albumin excretion between 30 and 300 mg/day 
(20 to 200 µg/min) is called microalbuminuria and, in 
patients with diabetes (particularly type 1 diabetes), is 
often indicative of early diabetic nephropathy, unless 
there is some coexistent renal disease. Protein excretion 
above 300 mg/day (200 µg/min) is considered to 
represent macroalbuminuria (also called overt proteinuria, 
clinical renal disease, or dipstick positive proteinuria).6 In 
general, immunoassay methods are the standard for 
measurement of microalbuminuria, and comprise four 
different techniques. These include, RIA 
(radioimmunoassay), ELISA (enzyme-linked immuno-
sorbent assay), RID (radioimmunodiffusion) and 
Immunoturbidometry. These four methods have a similar 
level of sensitivity and specificity, and are used in different 
areas according to the resources available.7 
Immunoturbidometry is more frequently used because of 
its greater simplicity. 
Microalbuminuria is considered as a reliable predictor of 
nephropathy in diabetic patients. Early detection of 
microalbuminuria is pivotal because the condition at this 
stage is potentially reversible, and appropriate treatment 
may prevent progressive diabetic renal damage.8 
Diagnosis of microalbuminuria can be carried out by 
number of approaches however three most common 
methods used are measurement of albumin-to-creatinine 
ratio on a spot urine test, albumin from a 24-hour urine 
collection, and albumin from a timed collection (e.g.10 
hours overnight).9 Twenty-four hours’ quantitative 
assessment of albuminuria is considered as gold standard 
but it is time consuming and sometimes difficult for the 
patient to understand the voiding and collection 
precautions.10 Spot urinary test is practical with negligible 
collection errors. Role of spot urine test in the primary 
prevention of diabetic nephropathy is clearly understood 
to detect the change from normal urinary albumin 
excretion to microalbuminuria with regular follow up.11  
Predictive power of urinary proteins, changes over the 
time as the disease progresses. Positive test indicates 
disease duration of more than 05 years.12 There is no 
definitive “cure” for diabetic nephropathy, but if it is 
diagnosed at early stage, its progression can be slowed 
down with good glycemic and weight control, optimized 
blood pressure and other factors effecting its 
progression.13 This study was designed to evaluate the 
efficacy of spot urinary albumin excretion for detection of 
early diabetic nephropathy in comparison with 24 hours 
urinary proteins in patients with diabetes. 
Operational Definitions 
Diabetic nephropathy: It is a condition in diabetic 
patients that damages on kidney function. It starts with 
microalbuminuria, proteinuria and progresses to kidney 
failure. If we can detect microalbuminuria early then we 
can slow down the disease process, even reverse it in 
microalbuminuria stage. This is the stage in diabetic 
nephropathy when overt proteinuria is not present i.e. the 
routine dipstick proteinuria will be absent. However, they 
may have microalbuminuria detected on either 24-hour 
urine sample or spot urine microalbuminuria testing. The 
urine dipstick is also a relatively insensitive marker for 
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initial increases in protein excretion, not generally 
becoming positive until protein excretion exceeds 300 to 
500 mg/day. 
Spot urinary albuminuria  
It is an immunoturbidimetric technique by which 
microalbuminuria can be detected in a spot urine sample.   
24 hours urinary albumin 
 It is the gold standard method to calculate the renal loss 
of protein over 24 hours for the correct estimation of the 
proteins to access the renal failure.  
    P a t i e n t s  a n d  M e t h o d s  
This cross-sectional study was conducted at Nephrology 
Department, Pakistan Institute of medical Sciences, 
Islamabad, over 6 months’ time. In total 289 patients 
diagnosed with type 1 Diabetes (of more than 5 years 
duration) or type 2 diabetes of any duration, of either 
gender and negative for overt albuminuria on standard 
urinary dipstick done on two occasions were included in 
the study. Patients with overt proteinuria, known chronic 
kidney disease, patients with urinary tract infections, 
hematuria of any cause, nephrolithiasis, hypertension, 
febrile illness, patients recently using nephrotoxic drugs, 
chronic liver failure, hepato-renal syndrome, organ 
transplant, kidney transplant, liver transplant, 
immunocompromised states, HIV-AIDS, patients with 
known malignancy, those on chemotherapeutic agents 
and pregnant females were excluded from the study  
Data were collected on a specially designed performa. 
Institutional ethical committee approved this study and a 
written informed consent was obtained from all subjects.  
A random sample of 289 subjects with type 1 & 2 DM 
were included in the study, provided they were negative 
on routine urinary dipstick testing on two occasions in 
their initial outdoor visit using (Multistix 10, SG, Bayer, 
Bridgend, UK. Each Demographic details were 
documented. Each patient was provided, a plastic 
container with capacity of 4000ml for 24 hours collection 
of urine. Oral and written instructions on how to collect 24-
hour urine were given. Patients were directed to start the 
24 h urine collection immediately after discarding their first 
void of urine in the morning, and to include a final void at 
completion of the collection period. Between 7 and 9 AM, 
when patients went to the laboratory to deliver the 
collected urine, they were asked to collect (via the 
midstream technique) a fasting spot urinary sample for 
UAC. The renal status of the subjects was assessed by 
the serum creatinine levels. The study group subjects 
were requested to provide early morning urine sample for 
spot urine test or a sample (collected anytime between 8 
am – 8 pm) and 24 hours urine sample. The urinary 
albumin was estimated in both the 24 hours and spot 
urine samples. The two samples were processed 
immediately and analyzed by two different technicians; 
the values were unknown to each other.  
Urinary microalbumin was determined by the 
immunoturbidimetric method. Reference value was 0-25 
mg/l and range of 0-400 mg/L with a detection limit of 0.7 
mg/l. 24-hour urinary albumin excretion was determined 
by photometric test according to biuret method. SPSS 
version 12 was used to record and analyze the gathered 
data. Descriptive statistic and frequencies of the spot 
urine albumin and 24 hours urinary albumin were 
measured. The sensitivity, specificity, negative predictive 
value, positive predictive value, accuracy and efficacy of 
spot urine microalbumin test was calculated in 
comparison to 24-hour urine protein test.  
R e s u l t s  
The study included 289 patients with DM, who did not 
have overt proteinuria on routine urine dipstick testing on 
two occasions. Demographic characteristics of the 
patients are presented in Table 1.  
 
Table 1: Demographic characteristics of Study 
Population (n=289) 
Age (years) 
Range (Mean± SD) 
 
22-66(54.06±9.5) 
Gender         
 Males;        n(%)  
 Females;    n(%) 
 
155 (53.63) 
 134 (46.37) 
Type of DM 
 Type 1 DM;  n(%) 
 Type 2 DM;  n(%) 
 
 39 (13.49) 
250 (86.50) 
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Figure 1: 24 Hour urinary protein  
 
Among 289 patients with diabetes, 113 (39.1%) patients 
had positive 24-hour urine protein and 176 (60.9%) 
patients had negative 24-hour urine protein (Figure 1). 
Total 98 patients (33.9%) had positive spot urine 
microalbumin test and 191 (66.1%) had a negative spot 
urine microalbumin test (Figure 2).  
 
 
Figure 2: Microalbuminuria 
 
The calculated sensitivity (TP/TP+FN) of the spot urine 
microalbumin test in comparison to 24-hour urine protein 
test was 83%. The calculated specificity (TN/TN+FP) of 
the spot urine microalbumin test in comparison to 24-hour 
urine protein test was 97.7%. The calculated positive 
predictive value (PPV=TP/TP+FP) of the spot urine 
microalbumin test in comparison to 24-hour urine protein 
test was 96%. The calculated negative predictive value 
(NPV=TN/TN+FN) of the spot urine microalbumin test in 
comparison to 24-hour urine protein test was 90%.  
In total spot urinary microalbumin test, accuracy 
(TP+TN/TP+TN+FP+FN) was 92%. When the results of 
spot urine microalbumin test and 24-hour urinary protein 
test were compared using the chi-square test it was found 
that patients with a positive spot urine microalbumin test 
had a statistically significant probability of having a 
confirmed diabetic nephropathy on 24-hour urinary protein 
test; p= 0.00 (Table 2). 
D i s c u s s i o n  
Measurement of albumin excretion in a 24-h urine 
collection has long been the “gold standard” for 
quantitative evaluation of albuminuria in diabetic patients; 
however, collection errors due to improper timing and 
missed samples may lead to significant over- and 
underestimation of albuminuria. For convenience and 
consistency, the American Diabetes Association and the 
National Kidney Foundation have recently recommended 
measurement of albumin-to-creatinine ratio (ACR) in a 
random spot urine collection for the diagnosis of 
microalbuminuria. The guidelines recommended using a 
first-morning sample because of the potentially higher 
correlation with 24-h albumin excretion, but a random 
sample is also considered acceptable if a first-morning 
specimen is not available. The significance of 
microalbuminuria is that it is the predictor of clinical 
proteinuria and chronic renal failure in Insulin dependent 
diabetes mellitus (IDDM) and the early index of 
cardiovascular morbidity and mortality as well as diabetic 
nephropathy in non-insulin dependent diabetes mellitus 
(NIDDM). Therefore, it is important to assess the validity 
of a random urine sample as a screening test of diabetic 
nephropathy. Previous studies have also shown that 
albumin measurements in a random urine sample 
presented almost perfect accuracy for the screening of 
micro- and macroalbuminuria in diabetic patients and 
suggested it as a valid test in screening for diabetic 
nephropathy.14 The study clearly shows that the spot 
microalbuminuria test provides an equivalent result 
compared to 24 hours in both type 1 and 2 diabetics. Our 
Table 2: Efficacy of spot urine Microalbumin test 
           24-hour urine 
protein 
p-
value 
Positive Negative  
0.00 Spot urine 
microalbumin 
 
Positive TP = 94 FP = 4 
Negative FN = 19 TN =172 
60.9% 
39.1% 
33.9% 
66.1% 
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study also concludes that spot urine samples can be 
effectively used to detect microalbuminuria in patients of 
diabetes mellitus especially in the Pakistani subset of 
diabetics. 
Some patients have microalbuminuria at the time of 
diagnosis, which may be due to previously undiagnosed 
diabetes or some other disease that is responsible for the 
microalbuminuria. Microalbuminuria is associated with 
declining kidney function, progression to 
macroalbuminuria, and increased long-term mortality. 
However, remission to normoalbuminuria may occur. 
Factors associated with remission include short duration 
of microalbuminuria, better glycemic control, better blood 
pressure control, and use of ACE inhibitors or angiotensin 
receptor blockers. 
Diabetic nephropathy is the commonest cause of renal 
failure in End-Stage Renal Disease [ESRD]. Mortality 
rates in these patients during dialysis are much higher 
than they are for non-diabetic cases. Given the worldwide 
high prevalence of both diabetes and hypertension, and 
of renal involvement in both disorders, it is important to 
detect renal disease promptly–through screening for 
microalbuminuria– when it is still at the reversible stage, 
in order to reduce both mortality and treatment cost in 
those affected.  
In type 1 diabets, approximately 20 to 30 percent will have 
microalbuminuria after a mean duration of diabetes of 15 
years.15  Less than half of these patients will progress to 
overt nephropathy. Microalbuminuria may regress or 
remain stable in a substantial proportion, probably related 
to glycemic and blood pressure control. Various studies 
have reported that the renal prognosis of type 1 diabetes, 
including the rate of progression to ESRD, has 
dramatically improved over the last several decades.16 
The prevalence of progressive renal disease has 
generally been lower in type 2 diabetes than in type 1 
disease. However, current data suggest that the renal risk 
is equivalent in the two types of diabetes.3 In both types 
there is regression of microalbuminuria with good 
glycemic control.17 Apart from glycemic control various 
risk factors have been found associated with development 
of overt nephropathy in these patients. These include 
genetic susceptibility (more chances of nephropathy in 
patients having diabetic sibling or parent) age (increased 
risk with increasing age and increases duration of disease 
in type 2 diabetes/ lower risk in patients diagnosed before 
the age of 5 years in Type 1 diabetes), Obesity (increased 
BMI related to higher glucose level), hypertension, 
smoking and use of oral contraceptives etc.18-21 
Microalbuminuria is now widely recognized as a sign of 
abnormal vascular function and increased vascular 
permeability. It has also been considered the first 
indication of renal injury in patients with diabetes. In 
addition, accumulating evidence suggests that 
microalbuminuria is associated with a higher 
cardiovascular risk as well as with a higher mortality 
independent of other risk factors. Thus screening for 
microalbuminuria is currently recommended for all 
patients with diabetes or kidney disease because it also 
provides valuable information about their cardiovascular 
risk profile. In a study conducted on a total of 717 adult 
diabetic in Diabetes Centere in Tokyo, Japan, a strong 
relationship was found between ACRs measured from 
first-morning and spot urine samples, yielding a linear 
correlation on a logarithmic scale.22 Other studies have 
also proved that convenient and accurate protein: 
creatinine ratio on random urine samples is a reliable  
method for estimation and screening of early proteinuria 
than the quantification by collection of 24 hours urine 
samples 23-25 
C o n c l u s i o n  
Spot urine microalbumin test is a highly sensitive and 
specific tool in the diagnosis of early diabetic nephropathy 
with high positive predictive value. Spot urine 
microalbumin test offers the advantage of speed, 
simplicity and early diagnosis. Spot urine microalbumin 
test has fairly acceptable accuracy as compared to 24-
hour urine protein test. 
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